- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01383304
Aspirin Response in High Risk Patients With Coronary Artery Disease
Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?
Previous studies indicate that patients with cardiovascular disease have a variable response to aspirin. Despite treatment with aspirin a large number of patients suffer a myocardial infarction. This has given rise to the phenomenon "aspirin low-responsiveness". Laboratory aspirin low-responsiveness can be defined as the failure of aspirin to inhibit platelet production of thromboxane A2 or inhibit thromboxane-dependent platelet aggregation. Whether a low platelet response to aspirin results in an increased risk of future thrombotic events is of great clinical significance, but is still unknown.
The investigators hypothesize that patients with a reduced response to aspirin, determined by platelet aggregation using the apparatus Verify Now Aspirin and Multiplate, have a higher risk of thrombosis.
The purpose of this study is to investigate whether a higher incidence of cardiovascular events is found in patients with coronary artery disease (CAD) having a reduced biochemical response to aspirin compared with CAD patients having a normal biochemical response to aspirin. In addition to CAD, all patients have at least one of the following risc factors: previous myocardial infarction, type 2 diabetes mellitus and/or renal insufficiency.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Aarhus N, Danmark, 8200
- Department of Clinical Biochemistry, Aarhus University Hospital, Skejby
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
906 patients with CAD. In addition to CAD, all patients have at least one of the following risc factors: previous myocardial infarction, type 2 diabetes mellitus and/or renal insufficiency.
Eligible patients are identified in the Western Denmark Heart Registry.
Beskrivelse
Inclusion Criteria:
- Coronary artery disease verified by coronary angiogram
- Treatment with aspirin 75 mg/d for at least the previous 7 days
- Previous myocardial infarction more than one year ago (groups with previous myocardial infarction)
- Type 2 diabetes mellitus treated with oral antidiabetics and/or insulin (groups with type 2 diabetes mellitus)
- Renal insufficiency; glomerular filtration rate <60 ml/min at the time of blood sampling (groups with renal insufficiency)
Exclusion Criteria:
- Treatment with NSAIDs, clopidogrel, ticlopidine, dipyridamole, warfarin or any other drugs known to affect platelet function
- Ischemic vascular event within the previous 12 months
- Revascularization (angioplasty or coronary by-pass graft surgery) within the previous 12 months
- Platelet count <120 x 10^9/L or >450 x 10^9/L
- For patients without diabetes: fast glucose >7 mmol/L
- Unable to give informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke
Tidsramme: Evaluation after 3 years
|
Evaluation after 3 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Combined secondary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke
Tidsramme: Evaluation after 5 years
|
Evaluation after 5 years
|
Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death
Tidsramme: Evaluation after 3 and 5 years
|
Evaluation after 3 and 5 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Genotype according to pre-specified genetic single nucleotide polymorphisms (SNPs)
Tidsramme: Baseline
|
At the day of blood sampling, plasma samples are retrieved for DNA extraction.
DNA samples are used to evaluate if pre-specified genetic single nucleotide polymorphisms (SNPs) are associated with platelet aggregation levels.
|
Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Anne-Mette Hvas, MD, Ph.D, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, Hvas AM. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 2008;123(2):267-73. doi: 10.1016/j.thromres.2008.03.023. Epub 2008 May 21.
- Pedersen SB, Grove EL, Nielsen HL, Mortensen J, Kristensen SD, Hvas AM. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets. 2009 Sep;20(6):415-20. doi: 10.1080/09537100903100643.
- Hedegaard SS, Hvas AM, Grove EL, Refsgaard J, Rocca B, Davi G, Kristensen SD. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res. 2009 May;124(1):96-100. doi: 10.1016/j.thromres.2008.12.034. Epub 2009 Feb 11.
- Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010 Jun;103(6):1245-53. doi: 10.1160/TH09-08-0527. Epub 2010 Mar 29.
- Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res. 2010 Oct;126(4):e318-22. doi: 10.1016/j.thromres.2010.03.013. Epub 2010 May 7.
- Larsen SB, Neergaard-Petersen S, Grove EL, Kristensen SD, Hvas AM. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thromb Haemost. 2012 Jul;108(1):140-7. doi: 10.1160/TH12-01-0026. Epub 2012 Apr 26.
- Wurtz M, Nissen PH, Grove EL, Kristensen SD, Hvas AM. Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS One. 2014 Oct 31;9(10):e111816. doi: 10.1371/journal.pone.0111816. eCollection 2014.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 22527
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hjerteinfarkt
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
University Hospital, Strasbourg, FranceAvsluttetST Elevatation Myocardial Infarction (STEMI)Frankrike
-
VesalioRekrutteringSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
University of Southern CaliforniaAktiv, ikke rekrutterendeNSTEMI - Ikke-ST Segment Elevation MI | Akutt koronarsyndrom (ACS) | STEMI - ST Elevation Myocardial Infarction (MI) | Ustabil angina (UA)Forente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
Sichuan Provincial People's HospitalPåmelding etter invitasjonRest Gated Myocardial Perfusion Imaging ved hjertesviktKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering